Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
9.68-0.02 (-0.21%)
At close: 4:00PM EDT
9.67 -0.01 (-0.10%)
After hours: 07:46PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9.70
Open9.72
Bid9.67 x 1000
Ask9.75 x 4000
Day's Range9.66 - 9.83
52 Week Range8.24 - 13.30
Volume4,176,655
Avg. Volume8,385,264
Market Cap10.69B
Beta (5Y Monthly)1.45
PE Ratio (TTM)N/A
EPS (TTM)-3.63
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 27, 2017
1y Target Est11.47
  • Business Wire

    New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis

    AMSTERDAM, October 13, 2021--Teva Pharmaceuticals Europe BV, a European affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and St. Josef Hospital – Katholisches Klinikum Bochum (Bochum, Germany), presented today at ECTRIMS congress new analyses of the COBRA study, a real-world evidence study on the safety of COPAXONE® (glatiramer acetate or GA) used by mothers with multiple sclerosis (MS) during pregnancy and breastfeeding.

  • Motley Fool

    5 Warren Buffett Stocks to Buy Hand Over Fist for the Fourth Quarter

    If you've ever wondered why Wall Street and retail investors pay such close attention to billionaire Warren Buffett, it's because he has an impeccable moneymaking track record. Since taking over as CEO of Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) in 1965, the Oracle of Omaha has overseen the creation of nearly $600 billion in market value for shareholders, and delivered an average annual return of 20% for the company's Class A shares. Riding Buffett's coattails has long been a profitable venture.

  • Benzinga

    Teva Stops Production At US Plant After FDA Concerns: Report

    Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has temporarily stopped drug production at its Irvine plant in California to address issues raised by the FDA after a recent inspection. The Company did not specify the issues raised by the agency. Bloomberg reported that the production halt followed Teva's recall of more than 2.5 million vials of drugs in recent months, many of them cancer medications. The report said the vials might have been contaminated with mold owing to water leaks discovered

Advertisement
Advertisement